Triad Therapeutics Inc.

If large molecule therapeutics have largely been the province of biotech companies, Big Pharma has owned the small molecule side of drug discovery. But a number of companies formed in the last couple

Small companies are staking out niches where they think they can do a better job of turning hits into leads than Big Pharma. by Mary Stuart More than once, the nightly news has reported that a new dis

Big Pharma's valuations are depressed; biotech red-hot. But the valuation divide masks the subtler cracks dividing biotech's elite from a mass of undifferentiated technology providers. by Roger Longma

The flood of genomics data has raised the bar for what Big Pharma considers scientifically enabling. By Jeffrey Dvorin Last March, in a START-UP profile, the management of Cytokinetics Inc. spoke